Rocket


Overview
Financials
News + Filings
Key Docs
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
C4 Therapeutics, Inc. Create: Alert

All | News | Filings
Date FiledTypeDescription
10/03/2023 4 Anderson Kenneth Carl (Director) has filed a Form 4 on C4 Therapeutics, Inc.
Txns: Granted 6,617 shares @ $1.7, valued at $11.2k
10/03/2023 4 Dubin Glenn (Director) has filed a Form 4 on C4 Therapeutics, Inc.
Txns: Granted 6,470 shares @ $1.7, valued at $11k
10/03/2023 4 GROGAN DONNA ROY (Director) has filed a Form 4 on C4 Therapeutics, Inc.
Txns: Granted 8,089 shares @ $1.7, valued at $13.8k
08/08/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/08/2023 8-K Quarterly results
Docs: "C4 Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights Established Exclusive Licensing Agreement for CFT8919, an EGFR L858R BiDAC™ Degrader, with Betta Pharmaceuticals in Greater China for NSCLC&#59; U.S. IND Cleared"
07/25/2023 SC 13G Form SC 13G - Statement of acquisition of beneficial ownership by individuals:
07/12/2023 4 REYNO LEONARD (Chief Medical Officer) has filed a Form 4 on C4 Therapeutics, Inc.
Txns: Granted 61,300 shares @ $0
Granted 276,000 options to buy @ $3.5, valued at $966k
07/12/2023 3 REYNO LEONARD (Chief Medical Officer) has filed a Form 3 on C4 Therapeutics, Inc.
07/07/2023 SC 13G/A BlackRock Inc. reports a 4.3% stake in C4 Therapeutics, Inc.
07/05/2023 4 Anderson Kenneth Carl (Director) has filed a Form 4 on C4 Therapeutics, Inc.
Txns: Granted 3,976 shares @ $2.83, valued at $11.3k
07/05/2023 4 Dubin Glenn (Director) has filed a Form 4 on C4 Therapeutics, Inc.
Txns: Granted 3,887 shares @ $2.83, valued at $11k
07/05/2023 4 GROGAN DONNA ROY (Director) has filed a Form 4 on C4 Therapeutics, Inc.
Txns: Granted 4,858 shares @ $2.83, valued at $13.7k
06/16/2023 4 Anderson Kenneth Carl (Director) has filed a Form 4 on C4 Therapeutics, Inc.
Txns: Granted 26,000 options to buy @ $3.61, valued at $93.9k
06/16/2023 4 Bessen Laura (Director) has filed a Form 4 on C4 Therapeutics, Inc.
Txns: Granted 26,000 options to buy @ $3.61, valued at $93.9k
06/16/2023 4 DOWNEY BRUCE (Director) has filed a Form 4 on C4 Therapeutics, Inc.
Txns: Granted 26,000 options to buy @ $3.61, valued at $93.9k
06/16/2023 4 Dubin Glenn (Director) has filed a Form 4 on C4 Therapeutics, Inc.
Txns: Granted 26,000 options to buy @ $3.61, valued at $93.9k
06/16/2023 4 GROGAN DONNA ROY (Director) has filed a Form 4 on C4 Therapeutics, Inc.
Txns: Granted 26,000 options to buy @ $3.61, valued at $93.9k
06/16/2023 4 Koppikar Utpal (Director) has filed a Form 4 on C4 Therapeutics, Inc.
Txns: Granted 26,000 options to buy @ $3.61, valued at $93.9k
06/16/2023 4 Salter Malcolm (Director) has filed a Form 4 on C4 Therapeutics, Inc.
Txns: Granted 26,000 options to buy @ $3.61, valued at $93.9k
06/12/2023 SC 13G/A ArrowMark Colorado Holdings LLC reports a 3% stake in C4 Therapeutics, Inc.
05/04/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/04/2023 8-K Quarterly results
Docs: "C4 Therapeutics Reports First Quarter 2023 Financial Results and Recent Business Highlights Preclinical Data Presented at AACR Demonstrated CFT1946 is a Potent and Mutant-Selective BRAF V600 BiDAC™ Degrader&#59; Phase 1/2 Clinical Trial Enrolling Patients"
05/04/2023 EFFECT Form EFFECT - Notice of Effectiveness:
04/28/2023 ARS Form ARS - Annual Report to Security Holders:
04/28/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
04/28/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
04/18/2023 PRE 14A Form PRE 14A - Other preliminary proxy statements:
04/14/2023 SC 13G Form SC 13G - Statement of acquisition of beneficial ownership by individuals:
04/04/2023 4 Dubin Glenn (Director) has filed a Form 4 on C4 Therapeutics, Inc.
Txns: Granted 3,438 shares @ $3.2, valued at $11k
04/04/2023 4 Anderson Kenneth Carl (Director) has filed a Form 4 on C4 Therapeutics, Inc.
Txns: Granted 3,516 shares @ $3.2, valued at $11.3k
04/04/2023 4 GROGAN DONNA ROY (Director) has filed a Form 4 on C4 Therapeutics, Inc.
Txns: Granted 4,298 shares @ $3.2, valued at $13.8k
02/23/2023 8-K/A Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "C4 Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Business Highlights Phase 1 Dose Escalation Data from the Ongoing Phase 1/2 Clinical Trials of CFT7455, an IKZF1/3 MonoDAC™ Degrader, and CFT8634, a BRD9 BiDAC™ Degrader, Expected in 2H 2023"
02/23/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
02/23/2023 POS AM Form POS AM - Post-Effective amendments for registration statement:
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy